FDA Continues Enforcement Discretion On Some Changes To PMA And HDE Devices
The policy allows device developers to change some device materials or manufacturing practices without first alerting the agency, as long as the alterations are a result of manufacturing or supply chain issues.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
Sponsors of PMA or HDE-authorized devices can make some modifications in response to COVID-19 without first alerting the US FDA under a recent guidance document.
A recent Capitol Hill event drew speakers such as Newt Gingrich, Sen. Kirsten Gillibrand, and musician Al B. Sure to protest a Medicare contractor’s decision to restrict coverage of blood tests used to detect early signs of rejection or organ damage in transplant patients.